EVP 4593,
EVP-4593,
EVP4593,
N(4)-(2-(4-phenoxyphenyl)ethyl)-4,6-quinazolinediamine,
QNZ quinazolinediamine,
545380-34-5,
QNZ,
QNZ (EVP4593),
6-Amino-4-(4-phenoxyphenylethylamino)quinazoline,
EVP4593,
N4-(4-phenoxyphenethyl)quinazoline-4,6-diamine,
4-N-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine,
NF-kappaB Activation Inhibitor,
InSolution™ NF-kappaB Activation Inhibitor,
N4-[2-(4-Phenoxyphenyl)ethyl]-4,6-quinazolinediamine,
C22H20N4O,
EVP 4593,
EVP-4593,
AG-F-89549,
qnz-evp4593,
Curator_000005,
NF-kB activation inhibitor,
AC1LA9A8,
SCHEMBL157421,
CHEMBL522502,
GTPL6012,
QNZ(EVP4593),
CTK5A1521,
DTXSID00333507,
EX-A182,
QNZ solution, 20 mM in DMSO,
HMS3229K22,
HMS3402B14,
HMS3649N20,
HMS3652J12,
BCP07901,
CAY10470,
KS-00001D7G,
ZINC1489490,
2022AH,
2676AH,
IN1202,
MFCD06411436,
s4902,
AKOS022175523,
CCG-206870,
CS-1515,
LS41108,
EVP-4593 solution, 20 mM in DMSO,
4CA-1067,
AJ-26334,
AK-35592,
DA-42127,
HY-13812,
SC-96574,
AB0165862,
EVP4593, >=98% (HPLC),
RT-015179,
FT-0661997,
SW220245-1,
545380-34-5 solution, 20 mM in DMSO,
W-5334,
6-amino-4-(4-phenoxyphenylethylamino) quinazoline,
SR-01000946744,
CU-00000000003-1,
SR-01000946744-1,
6-Amino-4-[2-(4-phenoxyphenyl)ethylamino]quinazoline,
N4-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine,
N~4~-[2-(4-Phenoxyphenyl)ethyl]quinazoline-4,6-diamine,
6-Amino-4-(4-phenoxyphenylethylamino)quinazoline solution, 20 mM in DMSO,
QNZ quinazolinediamine,
D03BXA,
AIDS181298,
CID509554,
A4217,
A12748,
C562064,
4,6-Quinazolinediamine, N4-[2-(4-phenoxyphenyl)ethyl]-,
N(4)-(2-(4-phenoxyphenyl)ethyl)-4,6-quinazolinediamine,